

Beyond the Symptom: The Biology of Fatigue September 27 – 28, 2021

Cancer and Cancer Treatment Fatigue

Christine Miaskowski, RN, PhD

American Cancer Society Clinical Research Professor

School of Nursing

University of California, San Francisco





Disclaimer and Disclosures

Disclaimer

This certifies that the views expressed in this presentation are those of the author and do not reflect the official policy of the NIH.

Disclosure

This certifies that I, Christine Miaskowski have no financial relationship that is relevant to the subject matter of this presentation.




Objectives of Presentation

- State of the Science
 - Historical perspective
 - Epidemiology of cancer-related fatigue (CRF)
 - Definition of CRF
- Measures to evaluate CRF
- Phenotypic risk factors for CRF
- Mechanisms underlying CRF

Historical Perspective


- Research on CRF began in ~1993
 - 23,984 references in PubMed



- Research was based on patients' reports of the occurrence of this symptom
- Initial studies focused on measurement
 - Oncology Nursing Society supported early research on CRF
 - Model to study fatigue was based on the theoretical perspectives from pain research – multidimensional symptom

Epidemiology of CRF

- Most common symptom in cancer patients
- 80% of patients who receive chemotherapy and radiation therapy
- >75% in patients with metastatic disease
- Prevalence rate in survivors is unknown (~29%)
- During COVID-19 ~42%



Definition of CRF

A distressing, persistent, subjective sense of physical, emotional, and/or cognitive tiredness or exhaustion related to cancer or cancer treatment that is not proportional to recent activity and interferes with usual functioning. Compared with the fatigue experienced by healthy individuals, CRF is more severe, more distressing, and less likely to be relieved by rest.



www.bjfm.co.uk



Measures to Evaluate CRF


- Brief Fatigue Inventory severity 9 items
- Daily Fatigue Cancer Scale severity 3 items
- EORTC QLQ-C30 severity 1 item
- EORTC QLQ-FA12 physical, emotional, cognitive 12 items
- Fatigue Questionnaire severity 11 items
- Visual Analogue Fatigue Scale severity 18 items
- Fatigue Symptom Inventory severity, frequency, diurnal variation, interference 14 items
- Functional Assessment of Cancer Therapy Fatigue physical, social/family, emotional, functional –
 41 or 13 items
- Multidimensional Fatigue Inventory general, physical, reduced activity, reduced motivation 20 items
- Multidimensional Fatigue Symptom Inventory general, physical, mental, emotional, vigor 83 or 30 items
- Piper Fatigue Score-12 sensory, behavioral/severity, affective meaning, cognitive/ mood 12 items
- PROMIS CAT fatigue, sleep disturbance, sleep impairment Up to 20 items
- Schwartz Cancer Fatigue Scale Revised physical and perceptual 6 items


Phenotypic Risk Factors Risk Factors Methodologic Considerations

- Female gender
- Younger age
- Higher level of comorbidity
- Decreased level of physical activity
- Higher levels of co-occurring symptoms
 - Depression
 - Sleep disturbance
 - Cognitive dysfunction
- Higher levels of stress
 - General stress
 - Cancer-specific stress
 - Cumulative life stress


- Lack of consistent findings regarding
 - Social determinants of health
 - Disease and treatment characteristics
- Appropriate comparison group ????
 - Case controls
 - Use of clinically meaningful cutoff scores to dichotomize samples of oncology patients
- Focus on mean fatigue scores
 - Lack of evaluation in inter-individual variability in fatigue severity
 - Lack of studies on diurnal variations in fatigue severity

Inter-individual Variability in Evening Fatigue






Latent Profile Analysis of Evening Fatigue



- Younger age
- Higher education
- Being female
- Being White
- Having child care responsibilities
- Lower functional status
- Higher comorbidity
- Diagnosis of depression
- Higher levels of stress
- Higher levels of sleep disturbance

Latent Profile Analysis of Morning Fatigue



- Younger age
- Being female
- Not married/partnered
- Living alone
- Having a higher income
- Being unemployed
- Higher BMI
- Lower functional status
- Higher comorbidity
- Diagnosis of depression
- Higher levels of stress
- Higher levels of sleep disturbance

Purple indicates different from PM fatigue

Perturbed KEGG Pathways (FWER <.05)

03320

04080

04726

05145

04072

04015

01523

PPAR signaling pathway

Serotonergic synapse

RAP 1 signaling pathway

Antifolate resistance

Phospholipase D signaling pathway

Toxoplasmosis

Neuroactive receptor ligand interaction pathway

X

X

X


X

X

X

X

Number	Pathway Name	AM Fatigue	PM Fatigue
04145	Phagosome	X	Х
04144	Endocytosis	X	X
04062	Chemokine signaling	X	X
04612	Antigen processing and presentation	X	X
04060	Cytokine-cytokine receptor interaction	X	X
04672	Intestinal immune network for IgA production	Х	X
04695	Th17 cell differentiation	Х	Х
04010	MAPK signaling	Х	Х
04962	Relaxin signaling pathway	Х	
05320	Autoimmune thyroid disease	Х	
04921	Oxytocin signaling pathway	Х	



 Association — Stronger Association

SUMMARY

- Fatigue is a common problem across the continuum of cancer care
 - Significant impact on all aspects of quality of life
- Lack of consensus on measurement
 - Single versus multiple dimensions
 - Diurnal variations in fatigue
 - Correlations with objective measures of physical and cognitive function
- Extremely complex phenotype
 - Phenotypic risk factors warrant additional evaluation
 - Relationships between fatigue and stress (general, disease specific, cumulative life stress)
 - Relationship between stress and multiple co-occurring symptoms
- Extremely complex mechanism
- Can a biosignature for CRF be created to predict high risk patients?

Acknowledgements

- National Cancer Institute
- American Cancer Society
- Members of Symptom Management Research Group
- All of the patients who participated in our studies